MyFinsight
Home
Compare
Blog
About
Scribe Therapeutics, Inc. (SCTX)
Scribe Therapeutics, Inc. (SCTX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Free Cash flow
-$12,919K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Receivables from collaboration p...
Cash received from government gr...
Others
Negative Cash Flow Breakdown
Purchases of investments
Accruals and other current liabi...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
Net loss
-23,824
Depreciation expense
1,277
Loss on disposal of equipment
-4
Stock-based compensation expense
2,197
Interest expense
875
Change in fair value of convertible note
1,585
Net amortization/accretion on investment securities
-210
Amortization of right-of-use asset
281
Expensed deferred offering costs
0
Cash received from government grants
3,830
Receivables from collaboration partners
-5,985
Prepaid expenses and other current assets
-890
Other long-term assets
520
Accounts payable
-2,139
Deferred revenue
-1,850
Accrued license fees
1,725
Accruals and other current liabilities
-3,236
Operating lease liabilities
-616
Other non-current liabilities
434
Net cash used in operating activities
-12,892
Purchases of property and equipment
27
Maturities of investments
42,339
Purchases of investments
4,842
Net cash provided by investing activities
37,470
Proceeds from exercise of stock options
238
Payments of deferred offering costs
2,026
Net cash (used in) / provided by financing activities
-1,788
Net change in cash, cash equivalents and restricted cash
22,790
Cash, cash equivalents and restricted cash, at the beginning of the period
13,471
Cash, cash equivalents and restricted cash, at the end of the period
36,261
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$42,339K
Net cash provided by
investing activities
$37,470K
Canceled cashflow
$4,869K
Net change in cash,
cash equivalents and...
$22,790K
Canceled cashflow
$14,680K
Purchases of investments
$4,842K
Purchases of property and
equipment
$27K
Receivables from
collaboration partners
-$5,985K
Cash received from
government grants
$3,830K
Stock-based compensation
expense
$2,197K
Accrued license fees
$1,725K
Change in fair value of
convertible note
$1,585K
Depreciation expense
$1,277K
Prepaid expenses and
other current assets
-$890K
Interest expense
$875K
Other non-current
liabilities
$434K
Amortization of right-of-use
asset
$281K
Net
amortization/accretion on investment...
-$210K
Loss on disposal of
equipment
-$4K
Proceeds from exercise of
stock options
$238K
Net cash used in
operating activities
-$12,892K
Net cash (used in) /
provided by financing...
-$1,788K
Canceled cashflow
$19,293K
Canceled cashflow
$238K
Net loss
-$23,824K
Payments of deferred
offering costs
$2,026K
Accruals and other
current liabilities
-$3,236K
Accounts payable
-$2,139K
Deferred revenue
-$1,850K
Operating lease
liabilities
-$616K
Other long-term
assets
$520K
Buy us a coffee